



CUP 2015: Improving Patient Management & Outcomes

24 September 2015
Royal College of Physicians
London

Faculty

Chair: Dr F Anthony Greco

Sub chairs: Dr Harpreet S Wasan, Dr Richard Griffiths

Medical Oncology: Prof Nicholas Pavlidis, Dr F Anthony Greco, Dr Harpreet S Wasan, Dr Richard J Osborne

Pathology: Dr Karin Oien

MDT: Dr Richard Griffiths, Dr Sarah Ngan, Katy Low

Genomics, molecular profiling, precision medicine & patient access: Professor Mark Caulfield, Dr Rod Benson, Dr Piers Mahon

Palliative care: Dr Louise Mason

Epidemiology: A/Prof Claire Vajdic

Behavioural science: Prof Penelope Schofield

Patient experience: Karen Lomas, John Symons

Learning Objectives

- (a) To recognise the fundamentals of Carcinoma of Unknown Primary (CUP) and the unique factors contributing to the poor prognosis and suboptimal patient experience.
 - (b) To understand, from different perspectives, the challenges and opportunities of establishing and running an effective CUP MDT
 - (c) To learn about scientific advances in the diagnosis, management and treatment of CUP through current international CUP research (clinical and patient), considering where it may lead and how it may affect practice.
 - (d) To benefit from practical case studies and exchanges with faculty and colleagues with a view to improving the diagnosis and treatment of patients with CUP.
-

Programme/overleaf.....

PROGRAMME

0830-0900	Registration and refreshments		
0900-0920	Opening and Welcome.		
0900-0910	Welcome from the CUP Foundation; Patient perspective	J. Symons	
0910-0920	Chairman's introductory remarks	A. Greco	

PART I: INTRODUCTION

0920-1040	Chair: Dr Greco		
0920-0940	Clinical presentation and treatment – an overview	N. Pavlidis	
0940-1000	Histopathological diagnosis of CUP	K. Oien	
1000-1020	Epidemiology	C. Vajdic	
1020-1040	Part I Panel and audience discussion		Panel: A. Greco, N.Pavlidis K. Oien, C. Vajdic
1040 -1110	Break		

PART II: TRANSLATIONAL/CLINICAL RESEARCH

1110-1300	Chair: Dr Wasan		
1110-1130	The biology of CUP	N. Pavlidis	
1130-1150	Can Phenotypic Screening be deployed to determine the best chemotherapeutic strategy for CUP?	R. Benson	
1150-1220	Latest research: <i>USA</i>	A. Greco	
1220-1250	Latest research: <i>Australia</i>	P. Schofield	
1250-1300	Q & A		
1300-1400	Lunch		
1400-1445	Chair: Dr Greco		
1400-1430	Latest research: <i>UK (CUP-ONE)</i>	H. Wasan	
1430-1445	Part II Panel and audience discussion		Panel: A. Greco, N. Pavlidis, H. Wasan, P. Schofield, R. Benson, P. Mahon

PART III: MUO/CUP MDT PERSPECTIVES AND CLINICAL CASE PRESENTATIONS

1445-1615	Chair: R. Griffiths		
1445-1505	Network I: <i>Clatterbridge</i> (includes case)	R. Griffiths	
1505-1525	Network II: <i>GSTT</i> (includes case)	S. Ngan	
1525-1545	Network III: <i>Basildon & Thurrock</i> - the CNS perspective	K. Low	

1545-1615	Part III Panel and audience discussion		Panel: R. Griffiths, S. Ngan, K. Low, R. Osborne, L. Mason, K. Lomas
-----------	--	--	--

1615-1630	Break		
-----------	-------	--	--

PART IV: FUTURE PERSPECTIVES

1630-1730	Chair: Dr Wasan		
1630-1650	CUP and the 100,000 Genomes Project	M. Caulfield	
1650-1710	A new era of CUP diagnosis and therapy is here: why is there controversy and lack of global acceptance?	A. Greco	
1710-1725	Part IV Panel and audience discussion		Panel: H. Wasan, A. Greco, M. Caulfield
1725-1730	Chairman's closing remarks	A. Greco	

1730-1830	Drinks and announcement of the winning poster		
-----------	---	--	--

Terms used in the NICE Guideline (July 2010)

Malignancy of undefined primary origin (MUO)

Metastatic malignancy identified on the basis of a limited number of tests, without an obvious primary site, before comprehensive investigation.

Provisional carcinoma of unknown primary origin (provisional CUP)

Metastatic epithelial or neuro-endocrine malignancy identified on the basis of histology or cytology, with no primary site detected despite a selected initial screen of investigations, before specialist review and possible further specialised investigations.

Confirmed carcinoma of unknown primary origin (confirmed CUP)

Metastatic epithelial or neuro-endocrine malignancy identified on the basis of final histology, with no primary site detected despite a selected initial screen of investigations, specialist review, and further specialised investigations as appropriate.

Want to know what CUP patients thought of their care?

The CUP Foundation has commissioned research – recently published - from Southampton University which can be found in the research section of our website: <http://www.cupfoundio.org/research>

Experiences of Care of Patients with Cancer of Unknown Primary (CUP): Analysis of the 2010, 2011-12 & 2013 Cancer Patient Experience Surveys. Wagland R, Bracher M, Ibanez Esqueda A, Schofield P, Richardson A. *Southampton University, Health Sciences.* Sep 2015.

